Product Description
IAMA-6 is an early-stage compound that has shown encouraging in vitro and in vivo proof of concept results in idiopathic and secondary forms of autism. The compound is designed to directly target and inhibit NKCC1, a sodium-potassium chloride co-transporter responsible for maintaining chloride homeostasis in neurons. By improving chloride homeostasis, IAMA-6 inhibits neuronal hyperexcitability commonly associated with autism and other neurological disorders. Pre-clinical mechanistic studies have also demonstrated that IAMA-6 was well tolerated and did not induce diuresis. IAMA-6 has the potential to be developed for multiple autism spectrum disorders and other CNS indications including neurodevelopmental and neurodegenerative diseases. (Sourced from: https://iamatherapeutics.com/science/)
Mechanisms of Action: NKCC Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: IAMA Therapeutics
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Italy
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Epilepsy
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06300398 |
ECS_IAMA23_0101 | P1 |
Completed |
Epilepsy |
2024-10-10 |
12% |
2026-02-21 |